Related Experiment Video
Updated: Aug 19, 2026

Quantification of Plasmid-Mediated Antibiotic Resistance in an Experimental Evolution Approach
Published on: December 14, 2019
Theoretical considerations involving the pharmacokinetics of plasmid DNA
Makiya Nishikawa1, Yoshinobu Takakura, Mitsuru Hashida
1Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. makiya@pharm.kyoto-u.ac.jp
Abstract:
Success of in vivo gene therapy relies on the development of gene delivery technologies, by which a well-controlled transgene expression is achieved as far as the spatial and temporal profile of the expression is concerned. Because transgene expression only occurs in cells that are transduced with the gene administered, the tissue distribution of genes is an important factor determining the efficacy of in vivo gene transfer. Plasmid DNA is the simplest vector and its administration in naked or complexed form results in significant transgene expression in various organs. The route of administration, the use of cationic vectors and the administration technique greatly affects the tissue distribution of plasmid DNA and the subsequent transgene expression. Therefore, a clear understanding of the tissue distribution of naked and complexed plasmid DNA is a prerequisite for strategies for developing effective in vivo gene transfer methods. Pharmacokinetics translates the tissue distribution properties of plasmid DNA into quantitative parameters, which can be compared with parameters obtained under different conditions, or with physiological parameters such as blood flow rate. Here we discuss the pharmacokinetic evaluation of the tissue distribution characteristics of plasmid DNA, in the free and complexed forms.
Related Concept Videos
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Physiological Pharmacokinetic Models: Assumption with Protein Binding
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
Dosage Regimens: Partial Pharmacokinetic Parameters

